Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CLDX
Stock Latest News
Company Announcements
Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis
20d ago
CLDX
Premium
Company Announcements
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
29d ago
CLDX
Premium
Company Announcements
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
1M ago
CLDX
Premium
The Fly
Celldex price target raised to $24 from $21 at Barclays
2M ago
CLDX
Premium
Company Announcements
Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria
2M ago
CLDX
Premium
Company Announcements
Celldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment
2M ago
CLDX
Premium
Market News
These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
2M ago
CLDX
CNTA
Premium
Ratings
Celldex’s Promising Market Opportunity: Buy Rating Backed by Phase III Trial and Revenue Projections
2M ago
CLDX
Premium
Ratings
Celldex’s Strategic Advancement in Phase 3 Trials for Barzolvolimab: A Promising Opportunity in Chronic Inducible Urticaria Treatment
2M ago
CLDX
Premium
The Fly
Celldex announces initiation of Phase 3 trial of barzolvolimab
2M ago
CLDX
Premium
Ratings
Celldex’s Promising Clinical Progress and Strategic Initiatives Drive Buy Rating
3M ago
CLDX
Premium
Ratings
Celldex’s Promising Future: Strong Pipeline and Financial Position Drive Buy Rating
3M ago
CLDX
Premium
The Fly
Celldex price target lowered to $21 from $25 at Barclays
3M ago
CLDX
Premium
Ratings
Celldex’s Promising Pipeline and Strategic Advancements Justify Buy Rating
3M ago
CLDX
Premium
Company Announcements
Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress
3M ago
CLDX
Premium
Ratings
Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position
3M ago
CLDX
Premium
The Fly
Celldex reports Q3 EPS ($1.01), consensus (89c)
3M ago
CLDX
Premium
The Fly
Celldex appoints Lawver as Chief Commercial Officer
3M ago
CLDX
Premium
Ratings
Celldex’s Promising Phase II Trial Results Justify Buy Rating
3M ago
CLDX
Premium
Ratings
Celldex’s Promising Phase 2 Trial Results and Strong Financial Position Support Buy Rating
3M ago
CLDX
Premium
Ratings
Celldex’s Barzolvolimab Shows Promising Phase 2 Results, Justifying Buy Rating
3M ago
CLDX
Premium
The Fly
Celldex announces additional data on barzolvolimab
4M ago
CLDX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
